|
Volumn 15, Issue 8, 2015, Pages 2021-2022
|
Stratifying Patients Based on Epitope Mismatching: Ready for Primetime?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALLOANTIBODY;
AMINO ACID;
EPITOPE;
HLA A24 ANTIGEN;
HLA A9 ANTIGEN;
HLA ANTIBODY;
HLA ANTIGEN CLASS 2;
UNCLASSIFIED DRUG;
ACUTE GRAFT REJECTION;
ALLOGRAFT;
AMINO ACID SEQUENCE;
ANTIGEN ANTIBODY REACTION;
DONOR SELECTION;
EDITORIAL;
GRAFT RECIPIENT;
GRAFT SURVIVAL;
HAPLOTYPE;
HEALTH STATUS;
HIGH RISK PATIENT;
HLA MATCHING;
HUMAN;
IMMUNOGENICITY;
IMMUNOSUPPRESSIVE TREATMENT;
MANAGED CARE;
ORGAN TRANSPLANTATION;
OUTCOME ASSESSMENT;
PATHOGENICITY;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK FACTOR;
SENSITIVITY AND SPECIFICITY;
SEROLOGY;
STRUCTURE ANALYSIS;
TREATMENT INDICATION;
FEMALE;
GRAFT REJECTION;
IMMUNOLOGY;
MALE;
EPITOPES;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HISTOCOMPATIBILITY ANTIGENS CLASS II;
HUMANS;
MALE;
|
EID: 84937513364
PISSN: 16006135
EISSN: 16006143
Source Type: Journal
DOI: 10.1111/ajt.13343 Document Type: Editorial |
Times cited : (8)
|
References (8)
|